3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors

This publication has 10 references indexed in Scilit:

• (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors
  The Journal of Pharmacology and Experimental Therapeutics, 2008
• Synthesis of 2-bromo-7-methyl-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and 3-alkyl-2-bromo-3,5-dihydro-imidazo[4,5-d]pyridazin-4-one and their selective elaboration
  Tetrahedron Letters, 2008
• Dipeptidyl peptidase iv inhibitors and diabetes therapy
  Frontiers in Bioscience-Landmark, 2008
• 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
  Journal of Medicinal Chemistry, 2007
• Xanthine mimetics as potent dipeptidyl peptidase IV inhibitors
  Bioorganic & Medicinal Chemistry Letters, 2006
• Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus
  Endocrine Reviews, 2006
• Inhibitors of proline-specific dipeptidyl peptidases: DPP IV inhibitors as a novel approach for the treatment of Type 2 diabetes
  Expert Opinion on Therapeutic Patents, 2005
• GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells
  Diabetes/Metabolism Research and Reviews, 2003
• Gastric Inhibitory Polypeptide: the neglected incretin revisited
  Regulatory Peptides, 2002
• Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV
  Endocrinology, 1995